Long-acting injectable (LAI) pre-exposure prophylaxis (PrEP) has the potential to facilitate adherence and transform HIV prevention. However, little LAI PrEP research has occurred among women, who face unique barriers. We conducted 30 in-depth interviews with HIV-negative women from 2017–2018 across six sites (New York; Chicago; San Francisco; Atlanta; Washington, DC; Chapel Hill) of the Women’s Interagency HIV Study. Interviews were recorded, transcribed, and analyzed using thematic content analysis. Few women expressed interest in PrEP and when prompted to choose a regimen, 55% would prefer LAI, 10% daily pills, and 33% said they would not take PrEP regardless of formulation. Perceived barriers included: (1) the fear of new—and perceived untested—injectable products and (2) potential side effects (e.g., injection-site pain, nausea). Facilitators included: (1) believing shots were more effective than pills; (2) ease and convenience; and (3) confidentiality. Future studies should incorporate women’s LAI PrEP-related experiences to facilitate uptake.

长效注射剂 (LAI) 暴露前预防 (PrEP) 具有促进依从性和改变 HIV 预防的潜力。然而，针对面临独特障碍的女性的 LAI PrEP 研究却很少。 2017 年至 2018 年，我们在妇女机构间艾滋病毒研究的六个地点（纽约、芝加哥、旧金山、亚特兰大、华盛顿特区、教堂山）对艾滋病毒阴性女性进行了 30 次深度访谈。使用主题内容分析对访谈进行记录、转录和分析。很少有女性表示对 PrEP 感兴趣，当被提示选择治疗方案时，55% 的女性更喜欢 LAI，10% 的女性更喜欢每日服用药物，33% 的女性表示无论配方如何，她们都不会服用 PrEP。感知到的障碍包括：(1) 对新的和感知到的未经测试的注射产品的恐惧，以及 (2) 潜在的副作用（例如注射部位疼痛、恶心）。推动者包括：（1）相信注射比药物更有效； (2) 轻松、方便； (3) 保密性。未来的研究应纳入女性 LAI PrEP 相关经验，以促进吸收。